Azithromycin for Injection

To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other bacterial drugs, azithromycin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Azithromycin for injection contains the active ingredient azithromycin, an azalide, a subclass of macrolide antibiotics, for intravenous injection. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,10,12,14-hepta-methyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring. Its molecular formula is C_{38}H_{72}N_{2}O_{12}, and its molecular weight is 749. Azithromycin has the following structural formula:

![Structural formula of azithromycin](image)

Azithromycin, as the monohydrate, is a white crystalline powder with a molecular formula of C_{38}H_{72}N_{2}O_{12}.H_{2}O and a molecular weight of 767.

Azithromycin for injection consists of azithromycin monohydrate and the following inactive ingredients: citric acid and sodium hydroxide. Azithromycin for injection is supplied in lyophilized form in a 10 mL vial equivalent to 500 mg of azithromycin, 384.5 mg of citric acid, and sodium hydroxide for pH adjustment. Reconstitution, according to label directions, results in approximately 5 mL of azithromycin for intravenous injection with each mL containing 100 mg azithromycin (from azithromycin monohydrate).

CLINICAL PHARMACOLOGY

Pharmacokinetics

In patients hospitalized with community-acquired pneumonia receiving single daily one-hour intravenous infusions for 2 to 5 days of 500 mg azithromycin at a concentration of 2 mg/mL, the mean C_{max} ± S.D. achieved was 3.63 ± 1.60 mcg/mL, while the 24- hour trough level was 0.20 ± 0.15 mcg/mL, and the AUC_{24} was 9.60 ± 4.80 mcg•h/mL.
The mean $C_{\text{max}}$, 24 hour trough and $\text{AUC}_{24}$ values were $1.14 \pm 0.14 \text{ mcg/mL}$, $0.18 \pm 0.02 \text{ mcg/mL}$, and $8.03 \pm 0.86 \text{ mcg} \cdot \text{h/mL}$, respectively, in normal volunteers receiving a 3-hour intravenous infusion of 500 mg azithromycin at a concentration of 1 mg/mL. Similar pharmacokinetic values were obtained in patients hospitalized with community-acquired pneumonia that received the same 3-hour dosage regimen for 2 to 5 days.

Plasma concentrations (mcg/mL ± S.D.) after the last daily intravenous infusion of 500 mg azithromycin

<table>
<thead>
<tr>
<th>Infusion Concentration</th>
<th>Time after starting the infusion (hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td>2 mg/mL, 1 hr *</td>
<td>2.98</td>
</tr>
<tr>
<td></td>
<td>±1.12</td>
</tr>
<tr>
<td>1 mg/mL, 3 hr †</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td>±0.13</td>
</tr>
</tbody>
</table>

* = 500 mg (2 mg/mL) for 2-5 days in Community-acquired pneumonia patients. † = 500 mg (1 mg/mL) for 5 days in healthy subjects.

The average $\text{CL}_t$ and $V_d$ values were 10.18 mL/min/kg and 33.3 L/kg, respectively, in 18 normal volunteers receiving 1000 to 4000-mg doses given as 1 mg/mL over 2 hours.

Comparison of the plasma pharmacokinetic parameters following the 1st and 5th daily doses of 500 mg intravenous azithromycin showed only an 8% increase in $C_{\text{max}}$ but a 61% increase in $\text{AUC}_{24}$ reflecting a threefold rise in $C_{24}$ trough levels.

Following single oral doses of 500 mg azithromycin (two 250 mg capsules) to 12 healthy volunteers, $C_{\text{max}}$, trough level, and $\text{AUC}_{24}$ were reported to be $0.41 \text{ mcg/mL}$, $0.05 \text{ mcg/mL}$, and 2.6 mcg·h/mL, respectively. These oral values are approximately 38%, 83%, and 52% of the values observed following a single 500-mg I.V. 3-hour infusion ($C_{\text{max}}$: 1.08 mcg/mL, trough: 0.06 mcg/mL, and $\text{AUC}_{24}$: 5 mcg·h/mL). Thus, plasma concentrations are higher following the intravenous regimen throughout the 24 hour interval. The pharmacokinetic parameters on day 5 of azithromycin 250 mg capsules following a 500 mg oral loading dose to healthy young adults (age 18 to 40 years old) were as follows: $C_{\text{max}}$: 0.24 mcg/mL, $\text{AUC}_{24}$: 2.1 mcg·h/mL. Azithromycin 250 mg capsules are no longer commercially available. Azithromycin 250 mg tablets are bioequivalent to 250 mg capsules in the fasting state.

Median azithromycin exposure (AUC 0-288) in mononuclear (MN) and polymorphonuclear (PMN) leukocytes following 1,500 mg of oral azithromycin, administered in single daily doses over either 5 days (two 250 mg tablets on day 1, followed by one 250 mg tablet on days 2 to 5) or 3 days (500 mg per day for days 1 to 3) to 12 healthy volunteers, was more than a 1000 fold and 800 fold greater than in serum, respectively.

Distribution

The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL.

Tissue concentrations have not been obtained following intravenous infusions of azithromycin. Selected tissue (or fluid) concentration and tissue (or fluid) to plasma/serum concentration ratios following oral administration of azithromycin are shown in the following table:

AZITHROMYCIN CONCENTRATIONS FOLLOWING A500 mg DOSE (TWO 250 mg CAPSULES) IN ADULTS

<p>| CORRESPONDING TISSUE | |
|------------------------|---|---|---|---|---|---|---|---|---|
| 0-288 | 0.24 | 2.1 | 4.9 | 9.8 | 19.6 | 39.2 | 78.4 | 156.8 | 235.2 |</p>
<table>
<thead>
<tr>
<th>TISSUE OR FLUID</th>
<th>TIME AFTER DOSE (h)</th>
<th>TISSUE OR FLUID CONCENTRATION (mcg/g or mcg/mL)</th>
<th>CORRESPONDING PLASMA OR SERUM LEVEL (mcg/mL)</th>
<th>(FLUID) PLASMA (SERUM) RATIO</th>
</tr>
</thead>
<tbody>
<tr>
<td>SKIN</td>
<td>72-96</td>
<td>0.4</td>
<td>0.012</td>
<td>35</td>
</tr>
<tr>
<td>LUNG</td>
<td>72-96</td>
<td>4</td>
<td>0.012</td>
<td>&gt;100</td>
</tr>
<tr>
<td>SPUTUM *</td>
<td>2-4</td>
<td>1</td>
<td>0.64</td>
<td>2</td>
</tr>
<tr>
<td>SPUTUM **</td>
<td>10-12</td>
<td>2.9</td>
<td>0.1</td>
<td>30</td>
</tr>
<tr>
<td>TONSIL ***</td>
<td>9-18</td>
<td>4.5</td>
<td>0.03</td>
<td>&gt;100</td>
</tr>
<tr>
<td>TONSIL ****</td>
<td>180</td>
<td>0.9</td>
<td>0.006</td>
<td>&gt;100</td>
</tr>
<tr>
<td>CERVIX ****</td>
<td>19</td>
<td>2.8</td>
<td>0.04</td>
<td>70</td>
</tr>
</tbody>
</table>

1 High tissue concentrations should not be interpreted to be quantitatively related to clinical efficacy. The antimicrobial activity of azithromycin is pH related and appears to be reduced with decreasing pH. However, the extensive distribution of drug to tissues may be relevant to clinical activity.

* Sample was obtained 2 to 4 hours after the first dose.
** Sample was obtained 10 to 12 hours after the first dose.
*** Dosing regimen of 2 doses of 250 mg each, separated by 12 hours.
**** Sample was obtained 19 hours after single 500 mg dose.

Tissue levels were determined following a single oral dose of 500 mg azithromycin in 7 gynecological patients. Approximately 17 hours after dosing, azithromycin concentrations were 2.7 mcg/g in ovarian tissue, 3.5 mcg/g in uterine tissue, and 3.3 mcg/g in salpinx. Following a regimen of 500 mg on the first day followed by 250 mg daily for 4 days, concentrations in the cerebrospinal fluid were less than 0.01 mcg/mL in the presence of non-inflamed meninges.

**Metabolism**

*In vitro* and *in vivo* studies to assess the metabolism of azithromycin have not been performed.

**Elimination**

Plasma concentrations of azithromycin following single 500 mg oral and I.V. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours. The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues.

In a multiple-dose study in 12 normal volunteers utilizing a 500 mg (1 mg/mL) one-hour intravenous-dosage regimen for five days, the amount of administered azithromycin dose excreted in urine in 24 hours was about 11% after the 1st dose and 14% after the 5th dose. These values are greater than the reported 6% excreted unchanged in urine after oral administration of azithromycin. Biliary excretion is a major route of elimination for unchanged drug, following oral administration.

**Special Populations**

*Renal Insufficiency*

Azithromycin pharmacokinetics were investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1,000 mg dose of azithromycin, mean $C_{\text{max}}$ and $AUC_{0-120}$ increased by 5.1% and 4.2%, respectively in subjects with mild to moderate renal impairment (GFR 10 to 80 mL/min) compared to subjects with normal renal function (GFR >80 mL/min). The mean $C_{\text{max}}$ and $AUC_{0-120}$ increased 61% and 35%, respectively in subjects with severe renal impairment (GFR <10 mL/min) compared to subjects with normal renal function (GFR > 80 mL/min). (See DOSAGE AND ADMINISTRATION.)
Hepatic Insufficiency
The pharmacokinetics of azithromycin in subjects with hepatic impairment have not been established.

Gender
There are no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment is recommended based on gender.

Geriatric Patients
Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of azithromycin following oral administration in older volunteers (65 to 85 years old) were similar to those in younger volunteers (18 to 40 years old) for the 5-day therapeutic regimen.

Pediatric Patients
Pharmacokinetic studies with intravenous azithromycin have not been performed in children.

Drug-Drug Interactions
Drug interaction studies were performed with oral azithromycin and other drugs likely to be co-administered. The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1 and the effect of other drugs on the pharmacokinetics of azithromycin are shown in Table 2.

Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in Table 1. No dosage adjustment of drugs listed in Table 1 is recommended when co-administered with azithromycin.

Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C\text{max} and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in Table 2. (See PRECAUTIONS, Drug Interactions.)

Table 1. Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Dose of Co-administered Drug</th>
<th>Dose of Azithromycin</th>
<th>n</th>
<th>Ratio (with/without azithromycin) of Co-administered Drug Pharmacokinetic Parameters (90% CI); No Effect = 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mean C\text{max} Mean AUC</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>10 mg/day × 8 days</td>
<td>500 mg/day PO on days 6-8</td>
<td>12</td>
<td>0.83 (0.63 to 1.08) 1.01 (0.81 to 1.25)</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>200 mg/day × 2 days, then 200 mg BID × 18 days</td>
<td>500 mg/day PO for days 16-18</td>
<td>7</td>
<td>0.97 (0.88 to 1.06) 0.96 (0.88 to 1.06)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetirizine</td>
<td>20 mg/day × 11 days</td>
<td>500 mg PO on day 7, then 250 mg/day on days 8-11</td>
<td>14</td>
<td>1.03 (0.93 to 1.14) 1.02 (0.92 to 1.13)</td>
</tr>
<tr>
<td>Didanosine</td>
<td>200 mg PO BID × 21 days</td>
<td>1,200 mg/day PO on days 8-21</td>
<td>6</td>
<td>1.44 (0.85 to 2.43) 1.14 (0.83 to 1.57)</td>
</tr>
<tr>
<td>Co-administered Drug</td>
<td>Dose of Co-administered Drug</td>
<td>Dose of Azithromycin</td>
<td>n</td>
<td>Ratio (with/without co-administered drug) of Azithromycin Pharmacokinetic Parameters (90% CI); No Effect = 1</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------</td>
<td>----------------------</td>
<td>---</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>400 mg/day × 7 days</td>
<td>1,200 mg PO on day 7</td>
<td>14</td>
<td>1.04* 0.95*</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>200 mg PO single dose</td>
<td>1,200 mg PO single dose</td>
<td>18</td>
<td>0.96 0.90 (0.86 to 1.08) (0.81 to 1.00)</td>
</tr>
<tr>
<td>Indinavir</td>
<td>800 mg TID × 5 days</td>
<td>1,200 mg PO on day 5</td>
<td>18</td>
<td>1.27 1.26 (0.89 to 1.81) (1.01 to 1.56)</td>
</tr>
<tr>
<td>Midazolam</td>
<td>15 mg PO on day 3</td>
<td>500 mg/day PO × 3 days</td>
<td>12</td>
<td>0.90 0.85 (0.81 to 1.01) (0.78 to 0.93)</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>750 mg TID × 11 days</td>
<td>1,200 mg PO on day 9</td>
<td>14</td>
<td>1.04 1.02 (0.98 to 1.11) (0.97 to 1.05)</td>
</tr>
<tr>
<td>Rifabutin</td>
<td>300 mg/day × 10 days</td>
<td>500 mg PO on day 1, then 250 mg/day on days 2-10</td>
<td>6</td>
<td>See footnote below NA</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>100 mg on days 1 and 4</td>
<td>500 mg/day PO × 3 days</td>
<td>12</td>
<td>1.16 0.92 (0.86 to 1.57) (0.75 to 1.12)</td>
</tr>
<tr>
<td>Theophylline</td>
<td>4 mg/kg IV on days 1, 11, 25</td>
<td>500 mg PO on day 7, 250 mg/day on days 8-11</td>
<td>10</td>
<td>1.19 1.02 (1.02 to 1.40) (0.86 to 1.22)</td>
</tr>
<tr>
<td>Theophylline</td>
<td>300 mg PO BID × 15 days</td>
<td>500 mg PO on day 6, then 250 mg/day on days 7-10</td>
<td>8</td>
<td>1.09 1.08 (0.92 to 1.29) (0.89 to 1.31)</td>
</tr>
<tr>
<td>Triazolam</td>
<td>0.125 mg on day 2</td>
<td>500 mg PO on day 1, then 250 mg/day on day 2</td>
<td>12</td>
<td>1.06* 1.02*</td>
</tr>
<tr>
<td>Trimethoprim/Sulfamethoxazole</td>
<td>160 mg/800mg/day PO × 7 days</td>
<td>1,200 mg PO on day 7</td>
<td>12</td>
<td>0.85 0.87 (0.75 to 0.97) (0.80 to 0.95)</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>500 mg/day PO × 21 days</td>
<td>600 mg/day PO × 14 days</td>
<td>5</td>
<td>1.12 0.94 (0.42 to 3.02) (0.52 to 1.70)</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>500 mg/day PO × 21 days</td>
<td>1,200 mg/day PO × 14 days</td>
<td>4</td>
<td>1.31 1.30 (0.43 to 3.97) (0.69 to 2.43)</td>
</tr>
</tbody>
</table>

NA - Not Available * - 90% Confidence interval not reported

Table 2. Drug Interactions: Pharmacokinetic Parameters for Azithromycin in the Presence of Co-administered Drugs (See PRECAUTIONS, Drug Interactions.)
Nelfinavir
750 mg TID × 11 days
1,200 mg PO on day 9

Rifabutin
300 mg/day × 10 days
500 mg PO on day 1, then 250 mg/day on days 2-10

6

See footnote below

NA

NA – Not available* - 90% Confidence interval not reported
Mean azithromycin concentrations one day after the last dose were 53 ng/mL when coadministered with 300 mg daily rifabutin and 49 ng/mL when coadministered with placebo.

**Microbiology**

Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus, interfering with microbial protein synthesis. Nucleic acid synthesis is not affected.

Azithromycin concentrates in phagocytes and fibroblasts as demonstrated by *in vitro* incubation techniques. Using such methodology, the ratio of intracellular to extracellular concentration was >30 after one hour incubation. *In vivo* studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.

Azithromycin has been shown to be active against most isolates of the following microorganisms, both *in vitro* and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert for azithromycin for injection.

**Aerobic and facultative gram-positive microorganisms**

*Staphylococcus aureus*

*Streptococcus pneumoniae*

NOTE: Azithromycin demonstrates cross-resistance with erythromycin-resistant gram-positive strains. Most strains of *Enterococcus faecalis* and methicillin-resistant staphylococci are resistant to azithromycin.

**Aerobic and facultative gram-negative microorganisms**

*Haemophilus influenzae*

*Moraxella catarrhalis*

*Neisseria gonorrhoeae*

**“Other” microorganisms**

*Chlamydia pneumoniae*

*Chlamydia trachomatis*

*Legionella pneumophila*

*Mycoplasma hominis*

*Mycoplasma pneumoniae*

Beta-lactamase production should have no effect on azithromycin activity.

Azithromycin has been shown to be active against most strains of the following microorganisms, both *in vitro* and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert for azithromycin tablets and azithromycin for oral suspension.

**Aerobic and facultative gram-positive microorganisms**

*Staphylococcus aureus*

*Streptococcus agalactiae*
Streptococcus pneumoniae
Streptococcus pyogenes

**Aerobic and facultative gram-negative microorganisms**

Haemophilus ducreyi
Haemophilus influenzae
Moraxella catarrhalis
Neisseria gonorrhoeae

**“Other” microorganisms**

Chlamydia pneumoniae
Chlamydia trachomatis
Mycoplasma pneumoniae

Beta-lactamase production should have no effect on azithromycin activity.

The following *in vitro* data are available, **but their clinical significance is unknown**.

At least 90% of the following microorganisms exhibit an *in vitro* minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoints for azithromycin. However, the safety and effectiveness of azithromycin in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

**Aerobic and facultative gram-positive microorganisms**

Streptococci (Groups C, F, G)
Viridans group streptococci

**Aerobic and facultative gram-negative microorganisms**

Bordetella pertussis

**Anaerobic microorganisms**

Peptostreptococcus species

Prevotella bivia

**“Other” microorganisms**

Ureaplasma urealyticum

Beta-lactamase production should have no effect on azithromycin activity.

**Susceptibility Testing Methods:**

When available, the results of *in vitro* susceptibility test results for antimicrobial drugs used in resident hospitals should be provided to the physician as periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports may differ from susceptibility data obtained from outpatient use, but could aid the physician in selecting the most effective antimicrobial.

**Dilution techniques:**

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method¹,² (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of azithromycin powder. The MIC values should be interpreted according to criteria
Diffusion techniques:
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. Once such standardized procedure requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15 mcg azithromycin to test the susceptibility of microorganisms to azithromycin. The disk diffusion interpretive criteria are provided in Table 1.

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Minimum Inhibitory Concentrations (mcg/mL)</th>
<th>Disk Diffusion (zone diameters in mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S</td>
<td>I</td>
</tr>
<tr>
<td><strong>Haemophilus spp.</strong></td>
<td>≤4</td>
<td>--</td>
</tr>
<tr>
<td><strong>Staphylococcus aureus</strong></td>
<td>≤2</td>
<td>4</td>
</tr>
<tr>
<td>Streptococci including S. pneumonia(^b)</td>
<td>≤0.05</td>
<td>1</td>
</tr>
</tbody>
</table>

\(^a\)The current absence of data on resistant strains precludes defining any category other than “susceptible”. If strains yield MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.\(^b\)Susceptibility of streptococci including S. pneumoniae to azithromycin and other macrolides can be predicted by testing erythromycin.

No interpretive criteria have been established for testing *Neisseria gonorrhoeae*. This species is not usually tested.

A report of “susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable. A report of “intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable; other therapy should be selected.

Quality Control:
Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures. Standard azithromycin powder should provide the following range of values noted in Table 2. Quality control microorganisms are specific strains of organisms with intrinsic biological properties. QC strains are very stable strains which will give a standard and repeatable susceptibility pattern. The specific strains used for microbiological quality control are not clinically significant.

<table>
<thead>
<tr>
<th>QC Strain</th>
<th>Minimum Inhibitory Concentrations (mcg/mL)</th>
<th>Disk Diffusion (zone diameters in mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Haemophilus influenzae</strong></td>
<td>ATCC 49247</td>
<td>1 – 4</td>
</tr>
<tr>
<td><strong>Staphylococcus aureus</strong></td>
<td>ATCC 29213</td>
<td>0.5-2</td>
</tr>
</tbody>
</table>
Staphylococcus aureus
ATCC 25923 21-26

Streptococcus pneumoniae
ATCC 49619 0.06-0.25 19-25

INDICATIONS AND USAGE
Azithromycin for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. As recommended dosages, durations of therapy, and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for dosing recommendations.

Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae in patients who require initial intravenous therapy.

Pelvic inflammatory disease due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis in patients who require initial intravenous therapy. If anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with azithromycin for injection.

Azithromycin for injection should be followed by azithromycin by the oral route as required. (See DOSAGE AND ADMINISTRATION.)

Appropriate culture and susceptibility tests should be performed before treatment to determine the causative microorganism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS
Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic.

WARNINGS
Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported. (See CONTRAINDICATIONS.) Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurrent soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present.

If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.
**Clostridium difficile** associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including azithromycin for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of **C. difficile**.

**C. difficile** produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of **C. difficile** cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against **C. difficile** may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of **C. difficile**, and surgical evaluation should be instituted as clinically indicated.

**PRECAUTIONS**

**General**

Because azithromycin is principally eliminated via the liver, caution should be exercised when azithromycin is administered to patients with impaired hepatic function. Due to the limited data in subjects with GFR <10 mL/min, caution should be exercised when prescribing azithromycin in these patients. (See CLINICAL PHARMACOLOGY, Special Populations, Renal Insufficiency.)

Azithromycin for injection should be reconstituted and diluted as directed and administered as an intravenous infusion over not less than 60 minutes. (See DOSAGE AND ADMINISTRATION.)

Local I.V. site reactions have been reported with the intravenous administration of azithromycin. The incidence and severity of these reactions were the same when 500 mg azithromycin were given over 1 hour (2 mg/mL as 250 mL infusion) or over 3 hours (1 mg/mL as 500 mL infusion). (See ADVERSE REACTIONS.) All volunteers who received infusate concentrations above 2 mg/mL experienced local I.V. site reactions and, therefore, higher concentrations should be avoided.

Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and *torsades de pointes*, have been seen in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarization.

Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy.

Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

**Information for Patients**

Patients should be directed to discontinue azithromycin and contact a physician if any signs of an allergic reaction occur.

Patients should be counseled that antibacterial drugs including azithromycin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When azithromycin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by azithromycin or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is
discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

**Drug Interactions**

Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (See ADVERSE REACTIONS.)

Although, in a study of 22 healthy men, a 5-day course of azithromycin did not affect the prothrombin time from a subsequently administered dose of warfarin, spontaneous post-marketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.

Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered. (See CLINICAL PHARMACOLOGY, Drug-Drug Interactions.) When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine. Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. No dosage adjustment of either drug is recommended when azithromycin is coadministered with any of these agents.

Interactions with the drugs listed below have not been reported in clinical trials with azithromycin; however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction. Nonetheless, they have been observed with macrolide products. Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised:

- **Digoxin** - elevated digoxin concentrations.
- **Ergotamine or dihydroergotamine** - acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
- **Terfenadine, cyclosporine, hexobarbital and phenytoin** - elevated concentrations.

**Laboratory Test Interactions**

There are no reported laboratory test interactions.

**Carcinogenesis and Mutagenesis and Impairment of Fertility**

Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. No evidence of impaired fertility due to azithromycin was found.

**Pregnancy**

Teratogenic Effects. Pregnancy Category B: Reproduction studies have been performed in rats and mice at doses up to moderately maternally toxic dose concentrations (i.e., 200 mg/kg/day by the oral route). These doses, based on a mg/m² basis, are estimated to be 4 and 2 times, respectively, the human daily dose of 500 mg by the oral route. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin
should be used during pregnancy only if clearly needed.

**Nursing Mothers**

It is not known whether azithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman.

**Pediatric Use**

Safety and effectiveness of azithromycin for injection in children or adolescents under 16 years have not been established. In controlled clinical studies, azithromycin has been administered to pediatric patients (age 6 months to 16 years) by the oral route. For information regarding the use of azithromycin for oral suspension in the treatment of pediatric patients, refer to the INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections of the prescribing information for azithromycin for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles.

**Geriatric Use**

Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of azithromycin following oral administration in older volunteers (65 to 85 years old) were similar to those in younger volunteers (18 to 40 years old) for the 5-day therapeutic regimen.

In multiple-dose clinical trials of intravenous azithromycin in the treatment of community-acquired pneumonia, 45% of patients (188/414) were at least 65 years of age and 22% of patients (91/414) were at least 75 years of age. No overall differences in safety were observed between these subjects and younger subjects in terms of adverse events, laboratory abnormalities, and discontinuations. Similar decreases in clinical response were noted in azithromycin- and comparator-treated patients with increasing age.

Azithromycin for injection contains 114 mg (4.96 mEq) of sodium per vial. At the usual recommended doses, patients would receive 114 mg (4.96 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. The total sodium content from dietary and non-dietary sources may be clinically important with regard to such diseases as congestive heart failure.

**ADVERSE REACTIONS**

In clinical trials of intravenous azithromycin for community-acquired pneumonia, in which 2 to 5 I.V. doses were given, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug. The majority of patients in these trials had one or more comorbid diseases and were receiving concomitant medications. Approximately 1.2% of the patients discontinued intravenous azithromycin therapy, and a total of 2.4% discontinued azithromycin therapy by either the intravenous or oral route because of clinical or laboratory side effects.

In clinical trials conducted in patients with pelvic inflammatory disease, in which 1 to 2 I.V. doses were given, 2% of women who received monotherapy with azithromycin and 4% who received azithromycin plus metronidazole discontinued therapy due to clinical side effects.

Clinical side effects leading to discontinuations from these studies were most commonly gastrointestinal (abdominal pain, nausea, vomiting, diarrhea), and rashes; laboratory side effects leading to discontinuation were increases in transaminase levels and/or alkaline phosphatase levels.

**Clinical**

Overall, the most common side effects associated with treatment in adult patients who received I.V./P.O. azithromycin in studies of community-acquired pneumonia were related to the gastrointestinal system with diarrhea/loose stools (4.3%), nausea (3.9%), abdominal pain (2.7%), and vomiting (1.4%) being the most frequently reported. Approximately 12% of patients experienced a side effect related to the intravenous infusion; most common were pain at the injection site (6.5%) and local inflammation (3.1%).
The most common side effects associated with treatment in adult women who received I.V./P.O. azithromycin in studies of pelvic inflammatory disease were related to the gastrointestinal system. Diarrhea (8.5%) and nausea (6.6%) were most commonly reported, followed by vaginitis (2.8%), abdominal pain (1.9%), anorexia (1.9%), rash and pruritus (1.9%). When azithromycin was co-administered with metronidazole in these studies, a higher proportion of women experienced side effects of nausea (10.3%), abdominal pain (3.7%), vomiting (2.8%), application site reaction, stomatitis, dizziness, or dyspnea (all at 1.9%).

No other side effects occurred in patients on the multiple dose I.V./P.O. regimen of azithromycin in these studies with a frequency greater than 1%.

Side effects that occurred with a frequency of 1% or less included the following:

**Gastrointestinal**: dyspepsia, flatulence, mucositis, oral moniliasis, and gastritis

**Nervous System**: headache, somnolence

**Allergic**: bronchospasm

**Special Senses**: taste perversion

**Post-Marketing Experience**

Adverse events reported with azithromycin during the post-marketing period in adult and/or pediatric patients for which a causal relationship may not be established include:

**Allergic**: Arthralgia, edema, urticaria and angioedema.

**Cardiovascular**: Arrhythmias including ventricular tachycardia and hypotension. There have been rare reports of QT prolongation and torsades de pointes.

**Gastrointestinal**: Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea rarely resulting in dehydration, pseudomembranous colitis, pancreatitis, oral candidiasis and rare reports of tongue discoloration.

**General**: Asthenia, paresthesia, fatigue, malaise and anaphylaxis (rarely fatal).

**Genitourinary**: Interstitial nephritis and acute renal failure and vaginitis.

**Hematopoietic**: Thrombocytopenia.

**Liver/Biliary**: Abnormal liver function including hepatitis and cholestatic jaundice, as well as rare cases of hepatic necrosis and hepatic failure, some of which have resulted in death.

**Nervous System**: Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity, nervousness, agitation and syncope.

**Psychiatric**: Aggressive reaction and anxiety.

**Skin/Appendages**: Pruritus, rarely serious skin reactions including erythema multiforme, Stevens-Johnson Syndrome and toxic epidermal necrolysis.

**Special Senses**: Hearing disturbances including hearing loss, deafness and/or tinnitus and rare reports of taste/smell perversion and/or loss.

**Laboratory Abnormalities**

Significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows: with an incidence of 4 to 6%, elevated ALT (SGPT), AST (SGOT), creatinine with an incidence of 1 to 3%, elevated LDH, bilirubin with an incidence of less than 1%, leukopenia, neutropenia, decreased platelet count, and elevated serum alkaline phosphatase.

When follow-up was provided, changes in laboratory tests appeared to be reversible.

In multiple-dose clinical trials involving more than 750 patients treated with azithromycin (I.V./P.O.),
less than 2% of patients discontinued azithromycin therapy because of treatment-related liver enzyme
abnormalities.

**DOSAGE AND ADMINISTRATION**

*(See INDICATIONS AND USAGE and CLINICAL PHARMACOLOGY.)*

The recommended dose of azithromycin for injection for the treatment of adult patients with community-
acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous
route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at
a single, daily dose of 500 mg, administered as two 250 mg tablets to complete a 7 to 10 day course of
therapy. The timing of the switch to oral therapy should be done at the discretion of the physician and in
accordance with clinical response.

The recommended dose of azithromycin for the treatment of adult patients with pelvic inflammatory
disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for
one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single,
daily dose of 250 mg to complete a 7 day course of therapy. The timing of the switch to oral therapy
should be done at the discretion of the physician and in accordance with clinical response. If anaerobic
microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic
activity should be administered in combination with azithromycin.

**Renal Insufficiency**

No dosage adjustment is recommended for subjects with renal impairment (GFR ≤80 mL/min). The mean
AUC$_{0-120}$ was similar in subjects with GFR 10 to 80 mL/min compared to subjects with normal renal
function, whereas it increased 35% in subjects with GFR <10 mL/min compared to subjects with normal
renal function. Caution should be exercised when azithromycin is administered to subjects with severe
renal impairment. (See CLINICAL PHARMACOLOGY, Special Populations, Renal Insufficiency.)

**Hepatic Insufficiency**

The pharmacokinetics of azithromycin in subjects with hepatic impairment have not been established. No
dose adjustment recommendations can be made in patients with impaired hepatic function (See
CLINICAL PHARMACOLOGY, Special Populations, Hepatic Insufficiency.)

No dosage adjustment is recommended based on age or gender. (See CLINICAL PHARMACOLOGY,
Special Populations.)

**The infusate concentration and rate of infusion for azithromycin for injection should be either 1
mg/mL over 3 hours or 2 mg/mL over 1 hour. Azithromycin for injection should not be given as a
bolus or as an intramuscular injection.**

**Preparation of the solution for intravenous administration is as follows:**

**Reconstitution**

Prepare the initial solution of azithromycin for injection by adding 4.8 mL of Sterile Water For Injection
to the 500 mg vial and shaking the vial until all of the drug is dissolved. Since azithromycin for injection
is supplied under vacuum, it is recommended that a standard 5 mL (non-automated) syringe be used to
eNSure that the exact amount of 4.8 mL of Sterile Water is dispensed. Each mL of reconstituted solution
contains 100 mg azithromycin. Reconstituted solution is stable for 24 hours when stored below 30°C or
86°F.

Parenteral drug products should be inspected visually for particulate matter prior to administration. If
particulate matter is evident in reconstituted fluids, the drug solution should be discarded.

**Dilute this solution further prior to administration as instructed below.**

**Dilution**
To provide azithromycin over a concentration range of 1 to 2 mg/mL, transfer 5 mL of the 100 mg/mL azithromycin solution into the appropriate amount of any of the diluents listed below:

Normal saline (0.9% sodium chloride)

1/2 Normal saline (0.45% sodium chloride)

5% Dextrose in water

Lactated Ringer’s solution

5% Dextrose in 1/2 normal saline (0.45% sodium chloride) with 20 mEq KCl

5% Dextrose in 1/3 normal saline (0.3% sodium chloride)

5% Dextrose in 1/2 normal saline (0.45% sodium chloride)

Normosol®-M in 5% dextrose

Normosol®-R in 5% dextrose

<table>
<thead>
<tr>
<th>Final Infusion Solution Concentration (mg/mL)</th>
<th>Amount of Diluent (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg/mL</td>
<td>500 mL</td>
</tr>
<tr>
<td>2 mg/mL</td>
<td>250 mL</td>
</tr>
</tbody>
</table>

It is recommended that a 500 mg dose of azithromycin for injection, diluted as above, be infused over a period of not less than 60 minutes.

**Azithromycin for injection should not be given as a bolus or as an intramuscular injection.**

Other intravenous substances, additives, or medications should not be added to azithromycin for injection, or infused simultaneously through the same intravenous line.

**Storage**

When diluted according to the instructions (1 mg/mL to 2 mg/mL), azithromycin for injection is stable for 24 hours at or below room temperature (30°C or 86°F), or for 7 days if stored under refrigeration (5°C or 41°F).

**HOW SUPPLIED**

Azithromycin for injection is supplied in lyophilized form under a vacuum in a 10 mL vial (NDC 60505-6076-4) equivalent to 500 mg of azithromycin for intravenous administration. Each vial also contains 384.5 mg of citric acid and sodium hydroxide.

These are packaged as follows:

10 vials of 500 mg NDC 60505-6076-4

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

*Normosol®-M in 5% dextrose and Normosol®-R in 5% dextrose are the trademarks of Hospira.*

**CLINICAL STUDIES**

**Community-Acquired Pneumonia**

In a controlled study of community-acquired pneumonia performed in the U.S., azithromycin (500 mg as a single daily dose by the intravenous route for 2 to 5 days, followed by 500 mg/day by the oral route to complete 7 to 10 days therapy) was compared to cefuroxime (2250 mg/day in three divided doses by the intravenous route for 2 to 5 days followed by 1000 mg/day in two divided doses by the oral route to
complete 7 to 10 days therapy), with or without erythromycin. For the 291 patients who were evaluable for clinical efficacy, the clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 277 patients seen at 10 to 14 days post-therapy were as follows:

<table>
<thead>
<tr>
<th>Clinical Outcome</th>
<th>Azithromycin</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cure</td>
<td>46%</td>
<td>44%</td>
</tr>
<tr>
<td>Improved</td>
<td>32%</td>
<td>30%</td>
</tr>
<tr>
<td>Success (Cure + Improved)</td>
<td>78%</td>
<td>74%</td>
</tr>
</tbody>
</table>

In a separate, uncontrolled clinical and microbiological trial performed in the U. S., 94 patients with community-acquired pneumonia who received azithromycin in the same regimen were evaluable for clinical efficacy. The clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 84 patients seen at 10 to 14 days post-therapy were as follows:

<table>
<thead>
<tr>
<th>Clinical Outcome</th>
<th>Azithromycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cure</td>
<td>60%</td>
</tr>
<tr>
<td>Improved</td>
<td>29%</td>
</tr>
<tr>
<td>Success (Cure + Improved)</td>
<td>89%</td>
</tr>
</tbody>
</table>

Microbiological determinations in both trials were made at the pre-treatment visit and, where applicable, were reassessed at later visits. Serological testing was done on baseline and final visit specimens. The following combined presumptive bacteriological eradication rates were obtained from the evaluable groups:

**Combined Bacteriological Eradication Rates for Azithromycin:**

<table>
<thead>
<tr>
<th>(at last completed visit)</th>
<th>Azithromycin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>S. pneumoniae</strong></td>
<td>64/67 (96%)</td>
</tr>
<tr>
<td><strong>H. influenzae</strong></td>
<td>41/43 (95%)</td>
</tr>
<tr>
<td><strong>M. catarrhalis</strong></td>
<td>9/10</td>
</tr>
<tr>
<td><strong>S. aureus</strong></td>
<td>9/10</td>
</tr>
</tbody>
</table>

aNineteen of twenty-four patients (79%) with positive blood cultures for S. pneumoniae were cured (intent to treat analysis) with eradication of the pathogen.

The presumed bacteriological outcomes at 10 to 14 days post-therapy for patients treated with azithromycin with evidence (serology and/or culture) of atypical pathogens for both trials were as follows:

<table>
<thead>
<tr>
<th>Evidence of Infection</th>
<th>Total</th>
<th>Cure</th>
<th>Improved</th>
<th>Cure + Improved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mycoplasma pneumoniae</strong></td>
<td>18</td>
<td>11 (61%)</td>
<td>5 (28%)</td>
<td>16 (89%)</td>
</tr>
<tr>
<td><strong>Chlamydia pneumoniae</strong></td>
<td>34</td>
<td>15 (44%)</td>
<td>13 (38%)</td>
<td>28 (82%)</td>
</tr>
<tr>
<td><strong>Legionella pneumophila</strong></td>
<td>16</td>
<td>5 (31%)</td>
<td>8 (50%)</td>
<td>13 (81%)</td>
</tr>
</tbody>
</table>

**ANIMAL TOXICOLOGY**

Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and pancreas) in dogs treated with azithromycin at doses which, expressed on the basis of mg/m², are approximately equal to the recommended adult human dose, and in rats treated at doses approximately one-sixth of the...
recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs given daily doses of azithromycin ranging from 10 days to 30 days. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (30 mg/kg dose) at observed $C_{\text{max}}$ value of 1.3 mcg/mL (six times greater than the observed $C_{\text{max}}$ of 0.216 mcg/mL at the pediatric dose of 10 mg/kg). Similarly, it has been shown in the dog (10 mg/kg dose) at observed $C_{\text{max}}$ value of 1.5 mcg/mL (seven times greater than the observed same $C_{\text{max}}$ and drug dose in the studied pediatric population). On a mg/m$^2$ basis, 30 mg/kg dose in the neonatal rat (135 mg/m$^2$) and 10 mg/kg dose in the neonatal dog (79 mg/m$^2$) are approximately 0.45 and 0.3 times, respectively, the recommended dose in the pediatric patients with an average body weight of 25 kg. Phospholipidosis, similar to that seen in the adult animals, is reversible after cessation of azithromycin treatment. The significance of these findings for animals and for humans is unknown.

Rx only
Manufactured for:
APOTEX CORP.
Weston,
FL 33326
Manufactured by:
Gland Pharma Ltd, Hyderabad 500 043
India
ML # 103 / AP / RR / 97 / F / R
April 2010
PSGG0106-00

REFERENCES

PRINCIPAL DISPLAY PANEL
Representative sample of labeling (see the HOW SUPPLIED section for complete listing):

PRINCIPAL DISPLAY PANEL - 500 mg*/vial
APOTEX CORP. NDC 60505-6076-4
AZITHROMYCIN for Injection
equivalent to 500 mg*/vial
Sterile, Rx only
10 Single Dose Vials
For Intravenous Infusion Only
Carton Label

PRINCIPAL DISPLAY PANEL
Representative sample of labeling (see the HOW SUPPLIED section for complete listing):

PRINCIPAL DISPLAY PANEL - 500 mg*/vial
APOTEX CORP. NDC 60505-6076-4
AZITHROMYCIN for Injection
equivalent to 500 mg*/vial
Sterile, Rx only
10 Single Dose Vials
For Intravenous Infusion Only
Label

AZITHROMYCIN
azithromycin for injection injection, powder, lyophilized, for solution injection
### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:60505-6076</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>INTRAVENOUS</td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin Monohydrate</td>
<td>Azithromycin</td>
<td>500 mg</td>
</tr>
<tr>
<td>(UNII: JTE4MNN1MD)</td>
<td>Anhydrous</td>
<td>in 10 mL</td>
</tr>
<tr>
<td>Azithromycin Anhydrous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(UNII: J2KLZ20U1M)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric Acid Monohydrate</td>
<td></td>
</tr>
<tr>
<td>(UNII: 2968PHW8QP)</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE (UNII: 55X04QC32I)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:60505-6076-4</td>
<td>10 in 1 CARTON</td>
<td>04/25/2010</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>10 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA065501</td>
<td>04/25/2010</td>
</tr>
</tbody>
</table>

### Labeler

- APOTEX CORP. (845263701)

### Registrant

- Gland Pharma Limited (918601238)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gland Pharma Limited</td>
<td></td>
<td>918601238</td>
<td>analysis(60505-6076) , manufacture(60505-6076)</td>
</tr>
</tbody>
</table>

Revised: 12/2018

APOTEX CORP.